Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary

Anixa Biosciences

09/09/2026 21:43

Anixa Biosciences Inc ANIX.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended July 31, lower than the same quarter last year, when the company reported EPS of -7 cents.  The mean expectation of five analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -9 cents to -8 cents per share.
Reported revenue was zero​; analysts expected zero. 
Anixa Biosciences Inc's reported EPS for the quarter was a loss of 8 cents​.
The company reported a quarterly loss of $2.61 million.
Anixa Biosciences Inc shares had risen by 3.6% this quarter and lost 7.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Anixa Biosciences Inc is $9.50, about 69.5% above its last closing price of $2.90
This summary was machine generated from LSEG data September 9 at 08:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jul. 31 2026 
-0.09
-0.08
Beat
Apr. 30 2026 
-0.09
-0.07
Beat
Jan. 31 2026 
-0.09
-0.08
Beat
Oct. 31 2025 
-0.09
-0.09
Met